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Experimental immune complex-mediated glomerulonephritis in the
nonhuman primate. This study was undertaken to develop a model of
immune complex (IC)-mediated glomerulonephritis (GN) in the nonhu-
man primate that could be used in subsequent studies to examine
critically the role of the erythrocyte complement receptor (E-CR) in the
pathogenesis of IC-mediated disease. Cynomolgus monkeys were cho-
Sen for study because they constituatively express E-CR levels that are
either less than, equal to, or greater than that seen in normal man. After
immunization with bovine gamma globulin (BGG), the GN induction
protocol was begun in 10 cynomolgus by initiating daily i.v. adminis-
tration of BGG in amounts sufficient to achieve or exceed antigen!
antibody equivalence (assessed by the quantitative precipitin assay) for
precipitating antibody present in the plasma volume. We found that
within eight weeks of daily BGG administration all of the cynomolgus
developed IC-mediated GN, irrespective of the initial E-CR level of the
animals. However, the high E-CR cynomolgus tended to receive the
higher BGG doses because of higher initial antibody levels to BGG.
When the total number of glomerular deposits (determined by morpho-
metric studies) per total BGG dose for each animal was plotted against
the initial CRIE of that animal, there was a tendency for the animals
with higher CR/E levels to have a lower number of glomerular deposits!
BGG dose (r = 0.62, P = 0.06). Also, the total number of glomerular
deposits correlated with the severity of the GN. During the early weeks
of the GN induction protocol, the IC that formed in vivo (assessed by
infusion of '251-BGG) bound in large amounts to the circulating eryth-
rocytes of the cynomolgus with medium or high E-CR levels. However,
when tested after the onset of heavy proteinuria, which occurred
between weeks 5 and 8 of daily BGG administration, the IC that formed
in the circulation bound only poorly to circulating erythrocytes. By this
time the E-CR levels had declined to 43 9% of initial values (P <
0.01). This study demonstrates that: I) A workable model of IC-
mediated GN has been developed in the nonhuman primate. 2) During
the induction of GM, CRIE and the ability of the erythrocyte to bind IC
in vivo are decreased significantly. This suggests that an intact E-CR
system could play a role in the protection against IC-mediated disease.
However, further study will be needed to test that hypothesis critically.
The present model should be useful in such studies.
Experimental IC-mediated GN has been studied extensively
in a variety of nonprimate species to elucidate the pathogenesis
of the GN [reviewed in 1]. However, recent evidence suggests
that the pathogenesis of IC-mediated disease in the primate may
be different from that of the nonprimate in at least one impor-
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tant respect: primates have large numbers of CR1 in the
circulation, almost all of which are expressed on erythrocytes
[2, 3]. By contrast, nonprimates have large numbers of CR1
expressed on platelets [2, 31. The function of CR! on the
platelets of nonprimates is not clear. However, in primates the
"E-CR system" appears to be part of an IC-clearing and
processing mechanism [2, 3]. The erythrocyte-IC clearing
mechanism appears to act by binding complement opsonized IC
to E-CR thereby preventing the IC from depositing in vulnera-
ble organs such as the kidney. The IC bound to erythrocytes are
eventually removed from the circulation when the IC-bearing
erythrocytes traverse liver or spleen. The erythrocytes that
bore the IC then return to the circulation apparently able, once
again, to participate in the erythrocyte IC-clearing mechanism
[2, 3]. The existence of the erythrocyte IC-processing mecha-
nism is suggested by in vitro studies showing that E-CR acts as
cofactor for the Factor I-mediated degradation of C3b sites on
IC that are bound to E-CR [2, 3]. The "processed" IC are
rendered incapable of activating the terminal sequence of the
complement pathway because of the degradation of C3b to C3d
[2, 3]. Thus, the E-CR system, by providing an E-CR clearing
and processing mechanism [2, 3], may protect against the
development of IC-mediated disease.
The present study was undertaken to develop a model of
IC-mediated GN in the nonhuman primate that could be used to
test critically the role of the E-CR system in IC-mediated
disease. In addition, this study afforded an opportunity to
assess IC/E-CR interactions and changes in the E-CR system
under conditions that lead to the development of IC-mediated
GN. Cynomolgus monkeys, which are close relatives of the
rhesus monkey, were chosen for study because cynomolgus
have E-CR levels that span the range of man (mean CRIE 200 to
1200) [2, 3]. BGG was used as the antigen to induce GN because
previous studies in the rabbit suggest that BGG is as nephrito-
genic as the other heterolgous serum proteins (such as, BSA,
HSA) that are used commonly to induce experimental GN [4].
In addition, BGG is an immunoglobulin, and immunoglobulins
are natural constituents of glomerular immune deposits serving
either as specific antibody or as the targets for rheumatoid
factor or anti-idiotypic antibodies [5]. The method used in the
present study to induce GN is similar to that described by
Dixon, Feldman and Vazquez [4] and Holdsworth, Neale and
Wilson [6] in rabbits.
The present study demonstrates that a workable model of
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IC-mediated GN has been developed in the nonhuman primate.
In addition, this study documents for the first time that induc-
tion of IC-mediated disease in the primate is associated with
reductions in E-CR levels and impairment of the erythrocyte-IC
clearing mechanism.
Methods
Twelve cynomolgus were studied, seven females and five
males. Each was identified by a letter of the alphabet (C through
N). All animals were purchased from the Charles River Primate
Center (Port Washington, New York, USA). Prior to entering
our primate colony, they were observed for four weeks in
quarantine where they were found to be normal on physical
exam, to be free of tuberculosis, and to have normal values on
a comprehensive battery of clinical tests including urinalysis.
They were then transferred to our primate colony for study.
The diet consisted of monkey chow, fresh fruit and water ad lib.
The animals were evaluated approximately weekly by a veter-
inarian and were weighed weekly. To collect fresh urine sam-
ples, the collection pan at the bottom of the cage was cleaned
and all urine passed over the subsequent hour was collected.
Overnight urine samples were collected in the same fashion.
Procedures for handling the nonhuman primates
For routine procedures (drawing blood by venipuncture,
injecting antigen intravenously, physical examination, measur-
ing body weight) the animals were sedated with Ketamine 6
mg/kg given intramuscularly. For the performance of the closed
needle biopsy of the kidney, the animals were anesthetized
more deeply by repeating the Ketamine dose about 20 minutes
after the initial dose. For more prolonged studies such as
studying the fate of '251-BGG injected into the circulation
(Antigen binding and clearance protocol, see below), an endo-
tracheal tube was placed in the Ketamine-sedated animal for
Halothane anesthesia which was maintained until the end of the
protocol.
Renal biopsy technique
The biopsy was performed with the animal prone or in a
lateral position. The kidneys were localized by palpation and
one was selected for biopsy. A four inch Trucut percutaneous
kidney biopsy needle was used to obtain two biopsy cores from
the lower pole or mid-region of the kidney. The samples were
examined with a dissecting microscope to assess for the pres-
ence of glomeruli. Whenever possible, the biopsy sites in a
given animal were alternated between the two kidneys.
Immunization protocol
BGG (Calbiochem, San Diego, California, USA) was emul-
sified in Freund's complete adjuvant and injected intramuscu-
larly, 1 mg/kg body weight, in the hind leg of the animal. At
three to four weeks after the primary immunization, a BGG
boost (1 mg/kg in incomplete Freund's adjuvant) was injected
intramuscularly. If inadequate precipitating antibody levels
were present two weeks after the first boost, one to three
additional boosts were given at two week intervals.
Pilot study
The first four animals studied (C, D, E, and F) were the
subjects of a pilot study to determine the dose of antigen that,
when injected daily intravenously, resulted in the largest gb-
merular deposition of BGG. The pilot study was begun after the
animals had established satisfactory levels of precipitating
antibodies to BGG and was conducted as follows:
1. The level of precipitating antibody in each animal was
determined and expressed as the g of '251-BGG precipitat-
ed/ml of serum at the equivalence point of the quantitative
precipitin assay.
2. Three different doses of antigen were tested: a) high dose
corresponding to the amount of BGG that, theoretically,
would achieve conditions of antigen-antibody equivalence
for precipitating antibody contained in plasma volume
(which was taken as 4% of body weight); b) medium dose
(40% of the high dose); and c) low dose (10% of the high
dose).
3. Each animal received each dose level of antigen for five
consecutive days. The sequence in which the high, medium,
and low doses of BGG were given was varied from animal to
animal so that the possible effects of the sequence of
administration of the three different dose levels of antigen
were minimized.
4. On the fifth day of each five day period of antigen adminis-
tration, a renal biopsy was performed and the amount of C3,
IgG and 1gM deposited in glomeruli (using FITC-labeled goat
anti-human antibodies) was determined by semiquantitative
immunofluore scent microscopy.
The pilot study showed that the renal biopsies done at the
completion of the week of high dose BGG (conditions that
approximated or exceeded conditions of antigen/antibody
equivalence in the circulation) showed 1 + to 3 + glomerular
deposition of IgG, 1gM and C3, whereas the renal biopsies done
after one week of low or medium dose BGG showed negative or
1+ results for immunoproteins deposited in the glomerulus.
Thus, the high dose of BGG was selected for use in the GN
induction protocol (described below). The animals involved in
the pilot study were also subsequently enrolled in the GN
induction protocol except for cynomolgus F who died of
respiratory arrest because of anaphylaxis during the high dose
week of the pilot study.
GN induction protocol
Eleven animals were begun on this protocol in groups of 3 or
4. The sequence of study was as follows: (C, D, and E), (G, I,
K, and L), and (H, J, M and N). Cynomolgus I was withdrawn
from the GN induction protocol at week 2 because of severe
hemorrhage from the spleen as the result of an attempted closed
needle biopsy of the kidney. Thus, the results shown below are
from the 10 cynomolgus that completed the full GN induction
protocol.
Prior to starting the GN induction protocol, each animal had
baseline blood and urine studies (see below) and a renal biopsy.
Daily i.v. antigen infusion was then begun. Cynomolgus C, D,
and E received BGG 5.5 mg/kg/day throughout the GN induc-
tion protocol. In the other animals the initial dose of BGG was
determined from the result of the quantitative precipitin assay
performed just prior to the start of the GN induction protocol.
Thereafter the BGG dose to be given that week (starting on
Monday) was determined from the quantitative precipitin assay
done on the plasma sample obtained on the previous Monday.
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This procedure was adopted because with daily administration
of BGG, the precipitating antibody levels to BGG generally fell
progressively during the week. However, BGG was not admin-
istered on Saturday and Sunday. Thus, Monday precipitating
antibody levels were generally sharply higher than those of the
preceeding Friday. Therefore, precipitating antibody levels on a
given Monday were estimated more accurately from those
present on the previous Monday rather than those present on
the previous Friday. The BGG dose was adjusted weekly as
follows: if precipitating antibody levels rose, the antigen dose
was increased in proportion to the increase in precipitating
antibody levels. If the precipitating antibody levels fell, the
dose of BGG was not changed. Thus, this strategy of antigen
dosing maintained the animals at antigen-antibody equivalence
or in antigen excess. Each dose of BGG was given in 50 ml of
normal saline which was infused over 10 minutes.
The schedule of tests during the GN induction protocol was
as follows: daily tests, dipstick urinalysis; twice weekly tests,
quantitative precipitin assay each Monday and Friday (plasma
specimens, obtained before BGG administration); weekly tests,
complete urinalysis, 24 hour urine for protein (Coomassie blue
method) and creatinine. Special tests were renal biopsy per-
formed prior to BOG immunization, and after the onset of GN,
or at eight weeks, whichever came first. GN was defined
clinically as the onset of persistent heavy proteinuria: dipstick
urinary protein concentration equal to or exceeding 100 mgldl
(confirmed by testing with 20% sulfsosalicylic acid) for five or
more consecutive days. Mean CR/E was determined at the
beginning and at the end of the study in all animals. In addition,
in most animals the E-CR levels were determined periodically
during the GN-Induction Protocol. The CRIE measurements
were made 24 hours after the last infusion of BGG. At this time
almost all of the BGG had been cleared from the circulation, as
assessed by measurement of the clearance of 1251-BGG that was
periodically injected with the unlabeled BGG (Antigen binding
and clearance protocol below). Serum C3 and C4 levels were
done at the beginning and at the end of the GN induction
protocol and, in some studies, before, during and after a single
infusion of BGG. A CBC, differential and platelet count were
measured in most animals on at least one occasion before and
after the infusion of BGG.
Antigen binding and clearance protocol
This protocol studied the fate of '251-BGG injected into the
cynomolgus after the antibody response to BGG was fully
developed. In most animals, this protocol was executed before
the start of the ON-Induction Protocol, two weeks after the
start of the GN induction protocol, and after the onset of heavy
proteinuria. In the single animal that did not develop heavy
proteinuria (cynomolgus M) the last execution of the antigen
binding and clearance protocol was eight weeks after the start
of the GN induction protocol. The antigen binding and clear-
ance protocols were conducted as follows: a 22-gauge Angio-
cath was placed in a peripheral vein for infusion of fluids. For
withdrawal of blood samples, a 22-gauge Angiocath was placed
in the femoral artery percutaneously. In some animals blood
pressure was monitored by an automatic sphygmomanometer
placed on the arm. The experiment commenced with the
intravenous infusion of the animal's usual dose of BGG which
had been spiked with '251-BGG sufficient to provide at least
10,000 CPM/ml of blood. One ml blood samples were obtained
at —10 and at 0, 1, 2, 5, 10, 30, and 60 minutes after completion
of the BGG infusion. As each blood sample was obtained, a 0.2
ml portion was immediately placed on 1 ml of iced 50% percoll
(Sigma Chemical Co, St Louis, Missouri, USA) and centrifuged
at 350 g for 15 minutes, as described previously [71. Under these
conditions an erythrocyte fraction (erythrocytes and '251-BGG
bound to erythrocytes) migrates through the percoll to the
bottom of the tube while leukocytes, IC not bound to erythro-
cytes and free 1251-BGG remain at the surface of the percoll [71.
After centrifugation on percoll, the percoll fraction (containing
plasma and buffy coat cells) was separated from the erythrocyte
fraction, and the '251-CPM content of each fraction determined.
The percent of '251-CPM bound to erythrocytes was then
calculated. Previous studies have shown that '251-BGG injected
into the circulation of nonimmunized cynomolgus shows no
specific binding of the '251-BGG to erythrocytes [8].
Histologic and morphometric techniques
Light and immunofluorescent microscopy. A portion of each
biopsy sample was fixed in 10% formalin and embedded in
paraffin wax. Four micron sections were cut and stained with
hematoxylin and eosin and PAS. A qualitative assessment of
the renal histology was made by two observers blinded to the
origin of the specimen. For immunofluorescent microscopy, a
portion of each biopsy sample was immediately immersed in
liquid nitrogen, and 4 micron sections were cut and stained with
FITC-labeled rabbit anti-human IgG, 1gM, C3 or C4. The slides
were examined with a Zeiss epifluorescence microscope.
Routine and quantitative electron microscopy studies. Rou-
tine electron microscopy was performed on small samples from
each biopsy. One cubic millimeter blocks of tissue were immer-
sion fixed for 4 to 12 hours in 1% glutaraldehyde in Millonigs
phosphate buffer pH 7.4. After osmic acid post-fixation, dehy-
dration and embedding in Polybed, one micron sections were
obtained. Sections with large glomeruli, at least one tubule
width in from the edge of the section, were selected and
ultrathin 5 nm sections obtained. The sections were briefly
stained with lead citrate and uranyl acetate. Glomerular histo-
morphometry was performed with a Gatan video monitor
attached to a Hitachi 600 standard transmission electron micro-
scope. Three histomorphometric studies were performed on 3
to 4 glomeruli per biopsy sample as follows: 1) Glomerular
components. Standard point counting technique [9] was used to
determine the relative volumes of the various glomerular com-
ponents for each biopsy sample. A transparent grid containing
40 equally spaced points was attached to the video screen and
the identity of the glomerular component under each point was
registered. Randomly selected areas of each glomerulus were
viewed at 53,000 magnification to provide at least 800 points per
glomerulus and the fractional volumes of mesangial cell, mesan-
gial matrix, and glomerular basement membrane (GBM) were
calculated for each biopsy. 2) GBM deposits. Random GBM
regions encountered during the glomerular component determi-
nation were viewed at 41,000 magnification and the GBM length
measured on the video monitor. The extent of lamina rara
interna (LRI), lamina densa (LD) and lamina rara externa
(LRE) electron dense deposits was also directly measured on
the screen and the percent of LRI, LD and LRE involved with
electron dense deposits was calculated. 3) Mesangial deposits.
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Fig. 1. The frequency/distribution curve of mean CRIE in 64 unselected
cynomolgus monkeys evaluated in our laboratory.
Random mesangial matrix areas encountered during the glomer-
ular component determination were viewed at 41,000 magnifi-
cation. The number of points of the 40-point transparency grid
that fell on mesangial deposits and the number of points that fell
on mesangial matrix were determined. The percent of mesangial
matrix with deposits was then calculated for each glomerulus
and averaged for each biopsy.
Analytical techniques
BGG was labeled with 125! using IODO-GEN (Pierce Chem-
ical Co, Rockford, Illinois, USA) according to manufacturer's
instructions.
Erythrocyte CR levels were determined by methods de-
scribed previously [10]. In brief, a mouse monoclonal anti-
human CR1 antibody (El 1, provided by Dr. Nancy Hogg) was
purified from ascites using caprylic acid and ammonium sulfate
and labeled with l25J using IODO-GEN. In initial experiments,
increasing amounts of '251-El 1 were incubated with cynomol-
gus erythrocytes to determine the saturating dose of Eli. Based
on that dose, single point binding analysis was done to enumer-
ate mean CRIE. Nonspecific binding was measured by '251-El 1
binding to sheep erythrocytes.
Precipitating antibody levels were determined by adding
increasing amounts of '251-BGG in a constant volume (5 d) to
a constant volume (25 ji!) of serum. The mixtures were incu-
bated for 30 minutes at 37°C, and then overnight a 4°C. After
resuspending the mixtures in phosphate buffered saline and
centrifuging at 1200 g for 10 minutes (twice), the pelleted
radioactivity was measured to determine the percent of 125I
BGG precipitated. The equivalence point was taken as the
inflection point in the quantitative precipitin curve. Precipitat-
ing antibody levels were expressed as the jg BGG precipitat-
ed/mi of plasma at the equivalence point of the quantitative
precipitin curve.
IC present in plasma were determined by isokinetic sucrose
gradient analysis, as described previously [7].
Plasma C3 and C4 levels were determined by a standard
Initial
CR/Ea Sex
Weight
kg
Initial
a BGGb
Low CRJE
C <100 F 3.8 34
D <100 M 5.1 210
G <100 M 5.6 105
L <100 F 2.8 23
Medium CRIE
H 1330 F 3.3 23
I 1520 F 3.0 52
K 1250 F 2.7 7
High CR/E
E 3600 F 3.8 202
M 5400 M 6.1 51
N 3700 M 6.4 461
a Mean CR'E measured prior to immunization to BGG
b Precipitating antibody levels to BGG, expressed as ig BGG/ml of
plasma precipitated at equivalence, at the start of the GN induction
protocol.
nephelometry technique (Becton-Dickinson) in the clinical lab-
oratories of The Ohio State University Hospitals.
Statistical methods
All mean values are shown 1 SEM. Other statistical tests
used are described in relationship to the data.
Results
E-CR status of cynomolgus monkeys
In preparation for selecting the cynomolgus used in the GN
induction protocol, the mean CR! E of 64 unselected cynomol-
gus was measured. Figure 1 shows the frequency/distribution
curve for the mean CRIE for these animals. Analysis of this
curve (performed by Dr. Judith Westman, Department of
Pediatrics, The Ohio State University) indicates that the distri-
bution is consistent with a bimodal population (values above or
below 2000 CR/E) and conforms to the Hardy-Weinberg equi-
librium statement. Studies in humans have shown that there is
DNA restriction fragment length polymorphism that cone-
sponds to the expression of either high or low mean CRIE [11].
Thus, the expression of mean CRJE in the cynomolgus is
consistent with a pattern of inheritance determined by codom-
inant alleles, just as it is in man.
The mean CR/E of the cynomolgus selected for the GN-
Induction Protocol and other pertinent clinical characteristics
are shown in Table 1.
Outcome of the immunization protocol
As shown in Figure 2 all cynomolgus selected for the GN
induction protocol developed precipitating antibody levels to
BGG. As can be seen from Table 1, there was no clear
relationship between the development of precipitating antibody
levels to BGG and sex, weight, or E-CR status. To date, we
have immunized 18 cynomolgus to BGG (including those shown
in Fig. 2). All developed precipitating antibody to BGG within
the range shown in Figure 2.
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Table 1. Clinical characteristics of the cynomolgus subjected to the
GN induction protocol
n
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Outcome of the GN induction protocol
Figure 3 shows the clinical course and the renal biopsy
findings of Cynomolgus C, a representative cynomolgus sub-jected to the GN induction protocol. The onset of heavy
proteinuria was abrupt and was preceded by a decline in
precipitating antibody levels. This pattern, which resembles
that seen in rats injected daily with BSA [12], was observed in
6 of 10 animals (C, D, G, H, K, L). In three animals precipi-
tating antibody levels remained the same or rose prior to the
onset of heavy proteinuria (E, I, N). Figure 4 shows the
sequential changes in the urinary protein/creatinine ratio during
the GN induction protocol measured from overnight urine
collections in seven of the cynomolgus. All but cynomolgus L,
K and M developed nephrotic range proteinuria (>3 mg urinary
protein/mg urinary creatinine). Cynomolgus C, D, and E also
developed nephrotic range proteinuria (500 mgldl) as assessed
by dipstick. Figure 5 shows the sequential changes in serum
creatinine levels during the GN induction protocol. As can be
seen, three of the animals (D, H and N) developed renal
insufficiency. H and N later progressed to renal failure, even
though the BGG administration was stopped at eight weeks.
Urine sediment exams were done on all animals, usually each
Friday. All animals developed microscopic hematuria. C, D,
and E also developed abundant red cell cast formation. Urinary
red cell casts were seen only occasionally in the other cyno-
molgus.
All of the cynomolgus developed renal biopsy evidence of
GN. By light microscopy the GN consisted of mild to moderate
mesangial proliferation in seven animals (D, E, G, I, K, and L)
and severe mesangial and endothelial proliferation in three
animals (C, H, and N). In all animals, immunofluorescent
microscopy showed 2 to 4+ staining for IgG, 1gM and C3 in
both mesangium and peripheral capillary wall. The glomerular
electron microscopy findings were subjected to morphometric
analysis. These are shown in Table 2. As can be seen, ON was
associated with large numbers of deposits in mesangium and
glomerular capillary wall. Table 3 lists the clinical parameters of
GN for each of the animals at the onset of heavy proteinuria
(HP). The GN renal biopsies were done within eight days of the
onset of HP. By comparing the results of Table 2 to those of
Table 3 it can be seen that the animals with the worst GN by
clinical parameters (elevated serum creatinine and/or heavy
proteinuria) also had the largest number of glomerular electron-
dense deposits.
Factors possibly related to the patho genesis of the GN
The present studies were not designed to test critically the
role of specific pathogenetic factors in the development of GN.
Nevertheless, serial measurements of relevant parameters were
made before and during the GN induction protocol. Thus, it is
possible to make associations between these parameters and
the development of GN. The parameters measured are as
115 follows:
Mean antibody level, total BGG dose/kg body weight, and
mean degree of antigen excess. As can be seen from Table 3,
the animals with the most severe GN (based on increased serum
creatinine and/or urine protein/urine creatinine ratio greater
than 10) were cynomolgus D, H, I, K, and N. With the
exception of D, these animals were the ones maintained at the
highest degree of antigen excess and received the highest BGG
doses/kg/day.
E-CR levels. As can be seen from Table 3, there were no
striking differences with respect to the time to onset of heavy
proteinuria and the initial CRIE status (low, medium or high) of
the animals. However, as shown in Table 3, compared to the
animals with low CRJE, the animals with medium or high CRJE
had a numerically higher total BOG dose/kg/day (11.8 3.3 vs.
4.3 1.0, P = 0.08, unpaired t-test) and a higher degree of
antigen excess (9.0 2.3 vs. 4.6 0.9, P = 0.12, unpaired
t-test). In addition, Figure 6 shows that after two weeks of daily
high dose antigen infusion, the mean CR!E was reduced in the
animals who, prior to the start of the GN induction protocol,
had medium to high mean CR!E. The loss of an effectively
functioning erythrocyte-IC clearing mechanism in these animals
is suggested by the results shown in Figure 7, which shows the
sequential changes in the peak binding of IC to erythrocytes in
vivo measured during the antigen binding and clearance exper-
iments performed before and during the ON induction protocol.
Figure 7 shows that before and during the early weeks of the
ON induction protocol '251-BGG-containing IC bound in large
amounts to circulating erythrocytes, suggesting that the eryth-
rocyte-IC clearing mechanism was playing an important role in
clearing IC from the circulation. However, in relation to the
onset of GN, the '251-BOG-containing IC now showed little or
no binding to circulating erythrocytes. Thus, whatever protec-
tive effect the erythrocyte-IC clearing mechanism might have
been providing was apparently lost by exposure to daily high-
dose BGG administration.
Events prior to the onset of the GN induction protocol were
also associated with reductions in E-CR levels. This is shown
by comparing the E-CR levels measured in the cynomolgus
prior to undertaking the immunization to BGG (Table 1) to the
E-CR levels measured just prior to the start of the GN induction
protocol (Table 3). These reductions in E-CR levels occurred
gradually and were, apparently, the result of exposure of the
animal to BGG via primary immunization, the two to four BGG
(435)
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Ti me, days post-primary immunization
Fig. 2. Sequential changes in precipitating antibody levels (expressed
as g BGG precipitated at equivalence/cc of plasma)following primary
immunization in the 10 cynomolgus that were studied in the GN
induction protocol.
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Fig. 3. A) Clinical course of a representative cynomolgus monkey (C) subjected to the GN induction protocol. The BGG dose was given
intravenously daily except for Saturday and Sunday. Precipitating antibody levels are expressed in g BGG precipitated/cc of plasma at
equivalence in the quantitative precipitin assay. The quantitative precipitin assay was done each Monday and Friday on blood samples obtained
prior to BGG administration. The numbers shown at each point in the curve showing the sequential changes in precipitating antibody levels are
the % of antigen precipitated at equivalence. Proteinuria was determined daily by Chem-strip (results indicated by bars) and onfirmed by weekly
measurement of 24 hour urine for protein by Coomassie blue. The renal biopsy was performed on the Monday of the second week of proteinuria.
Renal biopsy findings in cynomolgus C were at the onset of heavy proteinuria. B) Light microscopy (low power) showing mild proliferative
glomerulonephritis. (PAS, magnification 20 x). C) Light microscopy (high power) showing a mild but diffuse increase in glomerular cellularity.
(PAS, magnification 40 x). D) Immunofluorescent staining with FITC conjugated anti-human IgG demonstrating granular deposits of IgG in the
mesangium and glomerular basement membrane. (magnification 40 x). E) Electron microscopy showing expanded mesangium with electron dense
deposits: large subepithelial deposits and smaller lamina densa deposits in the peripheral glomerular basement membrane. (magnification 7,500 X
Insert: higher magnification showing detail of capillary wall deposits. (magnification 36,000 x). Abbreviations and symbols are: M, mesangium; E,
endothelial cell; large arrow, lamina rara externa deposits, arrowhead, lamina densa deposit. Fig. 3 continued on next page.
boosts, and the one to three BGG infusion studies that were
performed in each animal prior to the start of the GN induction
protocol. Although the E-CR levels decreased in the animals
with medium or high mean CRIE in the three to four weeks prior
to the start of the GN induction protocol, in all animals the
E-CR levels were stable in the week prior to starting the GN
induction protocol. Thus, the acute changes in E-CR levels
shown in Figure 6 occurred against a background of stable
E-CR levels.
To assess whether the initial E-CR status (low, medium or
high CR/E) of the monkey was related to the extent of glomer-
ular deposit, the following analysis was undertaken: 1) for each
animal the total capillary wall deposits (sum of deposits in LRI,
LD, and LRE), and mesangial deposits were determined for the
GN renal biopsies (data taken from Table 2); 2) for each animal,
the total capillary wall deposits and the mesangial deposits were
each factored by the total BGG dose/kg given to that animal up
to the time of the renal biopsy. This was done to adjust for the
fact that total capillary wall deposits and mesangial wall depos-
its correlated with the BGG dose/kg (r = 0.69, P < 0.001 for
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Table 2. Morphometric analysis of glomerular electron dense deposits on renal biopsy specimens obtained prior to the start of daily BGG
infusion, and after the onset of GN (5 to 8 weeks of daily BGG infusion)
Site of deposit
Mes LRI LD
-
LRE
Pre-GN GN Pre-UN GN Pre-GN GNName Pre-GN GN
Low CR/E
C 0.50 29.7 0.0 23.8 0.0 1.4 0.0 41.7
D 2.40 37.5 1.5 3.9 0.3 15.9 0.6 24.6
G 2.10 18.3 0.0 7.9 0.0 1.7 0.0 1.0
L ND 44.7 ND 0.0 ND 0.0 ND 11.1
Medium CR/E
H 6.1 32.3 1.7 3.9 0.7 12.4 0.0 13.5
I 4.6 30.9 1.5 4.7 2.0 0.0 0.2 9.9
K 2.7 24.0 0.5 14.5 0.3 0.0 0.3 2.6
High CRIE
M ND 11.3 ND 4.1 ND 5.1 ND 0.4
0.9 25.3 0.0 12.5 0.0 13.8 0.0 17.3
X SE 2.8 0.8 27.7 3.2a 0.7 0.3 8.4 2.5a 0.5 0.3 5.6 22b 0.2 0.1 13.6 4.4"
Results are expressed as percent of the given component of the glomerulus that is occupied by deposit. Abbreviations are: Mes, mesangium;
LRI, lamina rara interna; LD, lamina densa; LRE, lamina rara externa; ND, hot done.
a p < 0.01, b p < 0.05, by paired t-test comparing Pre-GN to GN values
Time, weeks of study
Fig. 4. Sequential changes in the ratio: urinary protein concentration/
urinary creatinine concentration, both in mg/dl, during the GN induc-
tion protocol. The results for each cynomolgus can be identified as
follows: Cynomolgus N had the highest final urine protein/urine creat-
mine ratio followed by cynomolgus H, K, I, G, L, and M. Sequential
measurement of the urine protein/urine creatinine ratio was not made in
cynomolgus C, D, and E. However, all three developed proteinuria
500 mg/dl as assessed by dipstick.
total capillary deposits; r = 0.57, P < 0.01 for mesangial
deposits), and for the fact that the medium and high CRIE
animals tended to receive higher doses of BGG/kg, compared to
the low CR/E animals (11.8 3.3 vs. 4.3 1.0 mg/kg/day, P =
0.08). 3) The correlation between CRJE of the animal at the start
of the GN induction protocol, and the extent of glomerular
electron dense deposits (capillary wall or mesangium)/total
BGG dose/kg was then calculated. Figure 8 shows the relation-
ship for capillary wall deposits. As can be seen, there was a
tendency for capillary wall deposits/BGG dose to be less in the
medium and high CR/E animals (r = 0.62, P = 0.06). The
correlation of mesangial deposits/BGG dose with E-CR was r =
0.45, P < 0.3 (data not shown).
Time, weeks of study
Fig. 5. Sequential changes in serum creatinine levels during the GN
induction protocol. The results for each cynomolgus can be identified as
follows: Cynomolgus H had the highest final serum creatinine level,
followed by cynomolgus N, D, M, G, L, K, E, I, and C.
Clearance of BGG from the circulation. The antigen binding
and clearance protocol experiments showed that the clearance
of 1251-BGG from the circulation was decreased during the latter
weeks of the ON induction protocol. That is, in the pre-GN
state (during the first 2 weeks of the GN induction protocol and
prior to the onset of heavy proteinuria) 44 11% of the
25I-BGG was cleared from the circulation in the first 10 minutes
after cessation of the '251-BGG infusion. By contrast, in the
post-GN state (week 5 to 8 into the GN induction protocol, and
after onset of heavy proteinuria), only 14 5% of the '251-BGG
was cleared from the circulation over this same time period (P
< 0.05, N = 7). We also estimated the clearance of '251-BGG
from the circulation for each animal in the pre-GN state and in
the post-GN state by calculating the slope of a plot of the
logarithm of the '251-CPM remaining in the circulation (ex-
pressed as a % of the peak '251-CPM) at 0, 1, 2, 5, 10, 30, and
60 minutes after completion of the '251-BGG infusion. This
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Table 3. Relationship between time-to-onset of heavy proteinuria (HP), change in serum creatinine levels, peak proteinuria, and factors that
could have influenced the development of GN in the cynomolgus
Onset Change Peak
Initial
mean
Final
CR/B
Mean C3
At
onset
C4
At
onsetAb level
Ag
ppt
Name
of HP
weeks
in ser
creat.a
U,,,i
Ucr"
CR1
EC
(8
weeks)
non-
pptd ppte
Ag
excess
in BGG
dos&' WBC'
Plate-
iet& Initial
of
HP Initial
of
HP
Low CRIE
C (F) 6.0 —0.1 ND" <100 ND 75 34 3.9 54 5.5 ND ND 110 60 12 11
D (M) 3.0 0.7 ND <100 ND 45 55 3.7 39 5.5 ND ND 98 69 15 15
O (M) 7,0 0.1 6.3 <100 ND 85 22 7.3 74 5.5 —48 —89 108 64 18 10
L(F) 7.0 0.1 1.2 <100 ND 21 32 2.4 24 1.9 —51 —20 90 93 13 15
Medium CRIE
H (F) 4.6 4.5 16.7 550 450 43 40 23.7 42 8.8 —60 —4 99 82 14 11
1(F) 5.2 0.0 10.0 960 490 45 22 13.0 62 6.1 +30 —65 100 49 15 8
K (F) 7.0 0.2 15.2 1080 520 47 21 9.1 66 8.9 —27 —62 96 84 14 15
High CRIE
E (F) 2.8 —0.1 ND 3200 ND 326 19 1.1 105 5.5 ND ND 121 95 16 12
M (M) No HP 0.0 0.5 1560 1200 22 38 6.7 39 4.8 —28 —13 1001 70 17 9
N (M) 4.8 1.6 32.2 1520 420 248 18 17.4 279 20 —63 —87 139 102 18 18
Mean 0.7 11.7 96 30 8.8 78 7.2 —35 —49 106 77 15 12
±SE ±0.4 ±3.8 ±33 ±3.8 ±2.3 ±23 ±1.5 ±12 ±13 ±5 ÷m ±1 -i°
Definition of time-to-onset of HP is the weeks of daily iv. BGG in the UN induction protocol until onset of GN (proteinuna  100 mg/dl for 5
or more consecutive days). For cynomolgus C, D, and E this includes the week they received "high dose" BOG in the pilot study.
a (Final serum creatinine — initial serum creatinine) in mg/dl
b Urine protein in mgldl / urine creatinine in mg/dl
C At start of ON induction protocol
"sg BGG precipitated/mi of plasma at the equivalence point of the quantitative precipitin assay. All values until the onset of HP were averaged
Nonprecipitating antibody level was taken as the percent of '251-BGG not precipitated at the equivalence point of the quantitative precipitin
assay; all values until the onset of HP were averaged
(Theoretical concentration of BGG/ml of plasma at complete mixing following the infusion of the BOG dose) / (BGG/ml of plasma at the
equivalence point of the quantitative precipitin assay from the plasma sample obtained just prior to infusion of the BOG dose); all values until the
onset of HP were averaged
g Theoretical amount of BGG precipitated in vivo/mi of plasma. This is extrapolated from the quantitative precipitin curve by locating on the
abscissa the concentration of BGG/ml of plasma theoretically achieved in vivo at complete mixing of the BGG dose and determining the percent
of the BGG dose that would have been precipitated by extrapolating to the ordinate of the quantitative precipitin curve. That value (%) is then
multipled by the actual dose of BGG infused intravenously. All values until the onset of HP were averaged.
' Total dose of BGG given until onset of HP/(total days/body weight in kg)
i Maximum percent decrease in white blood cell count following intravenous infusion of the BGG dose. See Figure 8 also.
Maximum percent decrease in platelet count following intravenous infusion of the BOG dose.
k Not done
at 8 weeks after start of ON induction protocol
m P < 0.005
P < 0.025, compared to initial values.
analysis also showed that over the 60 minutes of observation,
the clearance of 1251-BGG from the circulation was slower in the
post-GN state (—0.0042 ± 0.0012), compared to the pre-GN
state (—0.0084 ± 00026; P < 0.05).
Isokinetic sucrose gradient analysis was performed on
plasma samples taken at two minutes after completion of the
'251-BGG infusion in the antigen binding and clearance experi-
ments in four animals. In the pre-GN state the % of 1251 that
migrated in the 0-10 S fraction versus >50 S fraction was 6.7 ±
1.7% and 50 ± 5%, respectively. In the post-GN state the
corresponding measurements were 20.2 ± 14% versus 33.8 ±
9.2%. These differences did not achieve statistical significance.
However they are consistent with a trend towards a greater
degree of antigen excess in the post-GN state. This can slow the
clearance of IC from the circulation [131.
Plasma complement levels. Plasma complement can also
affect the binding of IC to erythrocytes and the clearance of IC
from the circulation [2, 3, 14, 15]. In the present study,
relatively modest changes in plasma C3 and C4 levels occurred
1600
1200
800
C.,
400
0-
Fig. 6. Sequential changes in mean CR/E in cynomolgus H, J, M, and
N, during the first 2 weeks of the GN induction protocol. BGG was
administered intravenously daily except for Saturday and Sunday. The
letters along the abscissa identify the day of the week on which the
measurement was made.
MTWThF T F M
Days of the week
Fig. 7. Sequential changes in the capacity of
cynomolgus erythrocytes to bind IC formed in
vivo before and during the GN induction
protocol. These results were obtained during
the performance of the antigen binding and
clearance experiments. The results shown are
those of the medium and high CR'E
cynomolgus. The animals that correspond to
the symbols are as follows: H (0), 1(X), K
(0), M (A), N (I). Peak binding of IC to
erythrocytes was observed by 2 mm after
infusion of their daily BGG dose, which had
been spiked with '251-BGG. The shaded area
is the range of "binding" of '25I-BGG-
containing IC erythrocytes in immunized
cynomolgus that have mean CRJE <100.
Other studies have demonstrated that
cynomolgus with mean CRJE <100 have no
measurable capacity to specifically bind IC
[8]. Thus, the shaded area represents
nonspecific binding of IC to erythrocytes. The
technique to measure binding of 1251-BGG
containing IC to erythrocytes in vivo is as
previously described [7].
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Fig. 8. Relationship between the CRIE level of the cynomolgus at the
start of the GN induction protocol, and glomerular capillary wall
deposits/totalBGG dose at the time of the GN renal biopsy. Glomerular
capillary wall deposits were taken as the sum of % of LRI, LD, and
LRE occupied by electron dense deposits (Table 2). BGG dose was the
total amount of BOG injected/total days of injection/kg body weight of
the animal (r = 0.62, P = 0.06).
(Table 3). These measurements were made 24 hours after the
last BGG dose. Previous studies have shown that large de-
creases in complement activity are needed to interfere impor-
tantly with the binding of IC to erythrocytes [14, 15]. Thus, it is
unlikely that the changes in the complement system contributed
importantly to the changes in the binding of IC to erythrocytes
or the clearance of IC from the circulation, observed in this
study.
Hematologic parameters. To determine the acute changes in
hematologic parameters that occurred as a result of a single
infusion of BGG, studies were carried out in eight animals
during the first two weeks of the GN induction protocol. The
seauential changes in hematologic parameters for the group are
0.50
the individual cynomolgus are shown in Table 3. As can be
seen, following the infusion of BGG, there were striking
changes in the total white blood cell count (that were nearly
totally accounted for by changes in polymorphonuclear leuko-
cytes), and platelets. The lymphocyte count tended to increase
but not significantly. Modest changes in hematocrit were also
seen but these were not significant. The observed changes in
polymorphonuclear leukocyte count and platelet count did not
correlate with the time of onset or severity of the glomerulone-
phritic process (Table 3).
General clinical outcomes of the GN induction protocol
2000 There was no significant change in body weight from thebeginning to the end of the GN induction protocol (mean change
—1.2 3%). Blood pressure levels were measured in four
animals during the antigen binding and clearance experiments.
The systolic blood pressure ranged between 70 and 110 mm Hg
at the start of the BGG infusion. Although the blood pressure
tended to decrease in each animal, the decrease was not
temporally related to the infusion of BGG. Rather the gradual
decrease in blood pressure (to nadir values of 60 to 80 mm Hg
systolic) seem best explained by the effects of general anesthe-
sia.
Routine hematology and blood chemistry tests were done at
the beginning and at the end of the GN induction protocol in
eight animals. The results of those studies are as follows: The
white blood cell count (cells/mm3) increased in five animals
(mean 6.5 0.9 to 10.8 1.7) and decreased in three animals
(mean 10.0 3.5 to 3.7 1.5). Two of the three animals
showing a decrease in white blood cell count (cynomolgus H
and N) were in renal failure at the time of this measurement.
The hematocrit decreased significantly 36 2 to 30 3 (P <
0.01). However, only H and N showed marked anemia (hema-
tocrit 16 and 19%, respectively). The following clinical chem-
istry values changed significantly by Wilcoxin Rank Sum test-
ing: blood urea nitrogen 22 2 to 64 19 mgldl, P < 0.02;
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35 to 650 170 lU/mi, P < 0.03; and SGOT 29 3 to 77
20 lU/mi, P < 0.05. The following clinical chemistry values
remained within normal limits and did not change significantly:
serum glucose, alkaline phosphatase, phosphorus, cholesterol,
bilirubin, SGPT, sodium and potassium.
Discussion
The present study demonstrates that it is feasible to study
experimental IC-mediated glomerulonephritis in the nonhuman
primate. The method used to induce GN involved daily intra-
venous infusion of BGG in which the initial dose was calculated
to achieve conditions of antigen/antibody equivalence for pre-
cipitating anti-BGG antibody contained in the plasma volume.
Thereafter, the dose of BGG was increased if the levels of
precipitating antibody to BGG increased. However, the dose of
BGG was not changed if precipitating antibody levels fell. As a
result of this strategy, the animals tended to be maintained in an
antigen excess because, with time, precipitating antibody to
BGG tended to decrease. Using this approach, all of the
cynomolgus developed GN within eight weeks of daily BGG
administration.
Although the present study cannot be used to assess critically
the role of the E-CR system as a protective factor in IC-
mediated disease, the present study does provide new insights
regarding the participation of the E-CR system in the glomeru-
lonephritic process. Those new insights are as follows:
1.) The IC that form in the circulation during the early phases
of the development of GN bind in large amounts to the
erythrocytes of animals with medium or high E-CR levels. The
IC are then cleared from the erythrocytes. The details of the
binding of IC to erythrocytes and clearance from the circula-
tion, according to E-CR levels, is presented in more detail
elsewhere [8]. The fact that the IC that form in the circulation
are able to bind to erythrocytes in large amounts suggests that
an intact E-CR system could play an important role in the
protection against IC-mediated disease.
2.) Repeated administration of antigen to primates immu-
nized to that antigen results in a progressive decrease in E-CR
levels. There are numerous reports that E-CR levels are low in
patients with SLE [2, 3, 16—23]. Some studies suggest that the
low E-CR levels in SLE patients are acquired [2, 3, 17, 19, 20,
22, 23], and may reflect SLE activity. Other studies suggest that
the low E-CR levels seen in SLE patients may be inherited [2,
3, 16, 18, 211. The present study documents that low E-CR
levels can be acquired during the induction of IC-mediated
disease. The mechanism of the decreased E-CR levels in
IC-mediated disease remains to be elucidated. However, we
have demonstrated that E-CR levels, as assessed by binding of
Eli to erythrocytes, decrease acutely during the infusion of
large doses of BGG into cynomolgus that have been immunized
to BGG and have high precipitating antibody levels to BGG [8].
The decrease in E-CR following a single infusion of BGG is
transient. That is, within 24 to 72 hours after infusing the BGG
into immunized cynomolgus, E-CR levels tend to return to
baseline levels [8]. However, as shown in Figure 6, after
repeated infusions of BGG, E-CR levels remain decreased.
Thus, the mechanism of the decrease in E-CR levels after a
single infusion of BGG may be different from that seen after
repeated infusions of BGG into the immunized cynomolgus. We
speculate that the progressive reduction in mean CR/E seen in
the cynomolgus immunized and repeatedly infused with BGG,
is the result of progressive destruction of CR on erythrocytes,
perhaps as a result of repeated interactions between IC bound
by E-CR and the mononuclear phagocyte system of liver and
spleen. Such a mechanism has been suggested previously by
Ross and coworkers [17].
3.) The reduction in E-CR levels associated with repeated
administration of antigen is associated with loss of the ability of
the E-CR system to bind the IC that form in the circulation.
There are at least three mechanisms that could explain this loss
of IC binding to E-CR: a) The IC that form in the circulation are
not capable of binding to E-CR. Late in the course of GN
100
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Fig. 9. Sequential changes in hematologic
parameters following the intravenous infusion of a
single dose of BGG into each of 8 immunized
cynomolgus. The dose of BGG was that used for GN
induction. These observations were made during the
first two weeks of the GN induction protocol.
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induction, the IC tended to be formed in antigen excess.
Previous studies have shown that IC formed in large degrees of
antigen excess have a decreased capacity to bind to E-CR [2, 31.
However, it is unlikely that differences in the degree of antigen
excess alone can explain the decreased binding of IC to
erythrocytes observed during the post-GN period, for the
following reasons: in cynomolgus I, the degree of antigen
excess measured during the antigen binding and clearance
protocol performed pre-GN was greater than that measured
post-GN (4.0 vs. 2.0), yet peak % binding of '251-BGG to
erythrocytes was greater (65% vs. 21%). Furthermore, in the
post-GN antigen binding and clearance protocol performed in
cynomolgus N, peak binding of '25I-BGG to erythrocytes was
markedly impaired (4%) at an antigen excess state of 4.4, a
value that was seen commonly in experiments in other cyno-
molgus that showed high levels of binding of '251-BGG to
erythrocytes. Thus, a high degree of antigen excess cannot
explain all of the instances of low binding of IC to erythrocytes
observed in the present study. b) The IC that form in the
circulation may not be sufficiently opsonized to bind to E-CR.
This possibility was not directly evaluated in the present
experiments. However, from Table 2 it can be seen that in most
cynomolgus, the degree of hypocomplementemia was mild and
should have permitted satisfactory opsonization of IC [14, 151.
c) The E-CR system may have sustained damage that rendered
it less capable of binding complement opsonized IC. Current
evidence suggests that the binding of an IC to E-CR involves
multiple C3b sites on the IC binding to a cluster of CR1 on the
erythrocyte [24—26] in which each CR1 have three potential
binding sites for C3b [27]. It is possible that repeated exposure
of the E-CR clusters bearing the IC, to the mononuclear
phagocyte system of liver and spleen results in damage to the
E-CR clusters. Thus, although substantial numbers of E-CR
might remain on the erythrocytes, the remaining E-CR might
not be in clusters suitable for binding IC. This hypothesis was
not tested in the present studies.
A definitive analysis of the factors responsible for the devel-
opment of GN in these primates is not possible because of the
relatively small number of animals studied. Nevertheless, cer-
tain interpretations seem justified. They are as follows:
1.) The presence of a high E-CR level does not prevent the
development of IC-mediated GN. All of the cynomolgus devel-
oped GN, regardless of E-CR level. Nevertheless, we suggest
that the present study should not be interpreted as showing that
the E-CR system is incapable of providing protection against
IC-mediated disease. That is, the animals with medium and high
E-CR levels tended to have higher antibody levels, to receive
higher antigen doses and, apparently, were exposed to larger IC
loads. Indeed, when the extent of glomerular capillary wall
electron dense deposits was factored by antigen dose/kg body
weight, we found that the animals with medium or high E-CR
levels tended to have fewer glomerular deposits compared to
the animals with low E-CR levels. Furthermore, the only animal
not to develop heavy proteinuria (cynomolgus M) had high
E-CR levels. Although cynomolgus M did not have high anti-
body levels or receive a high antigen dose, his antibody levels
and antigen dose were similar to those of the low mean CRIE
group (Table 3), all of whom did develop heavy proteinuria, and
one develoned imnaired kidney function (cvnomolgus D). Nev-
could play a protective role in IC-mediated GN is circumstan-
tial. Additional, definitive studies will be needed to determine
what role, if any, the E-CR system plays in IC-mediated GN.
2.) The severest GN was seen in the animals that were
maintained in a high degree of antigen excess or sustained high
antibody levels during the GN induction protocol. These cor-
relations can be inferred from data shown in Table 3. A high
degree of antigen excess would be expected to result in free
antigen in the circulation and the formation of smaller IC that
bind poorly to E-CR [3]. These events could worsen the GN by
rendering the erythrocyte-IC clearing mechanism useless. In
addition, the free antigen could lead directly to in situ IC
formation or be taken up by deposited IC. On the other hand,
free antigen in the circulation could have an ameliorating effect
on the GN by resulting in solubilization of IC deposited in tissue
[28]. However, over the range of antigen excess induced in the
present study, such an effect apparently did not predominate.
3.) Changes in circulating polymorphonuclear leukocytes and
platelets, plasma C3 and C4 levels, and nonprecipitating anti-
body levels occur but do not correlate with the time of onset or
the severity of the GN. This interpretation seems justified by
inspection of the data presented in Table 3.
In summary, the present studies show that the E-CR system
participates in the handling of IC that form in the circulation
and, apparently, is damaged by these IC/E-CR interactions. It
remains to be determined whether the erythrocyte E-CR system
is capable of providing an important level of protection against
IC-mediated disease. The model of experimental ON developed
in this study should be helpful in elucidating the role of the
E-CR system.
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